Drug Search Results
More Filters [+]

BAY86-5300

Alternative Names: bay86-5300, bay865300, bay86 5300
Latest Update: 2019-03-13
Latest Update Note: Clinical Trial Update

Product Description

Bayer was developing bay86-5300, an oral drug, for the treatment of Dysmenorrhea (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01892904)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BAY86-5300

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Endometriosis|Contraception|Acne Vulgaris|Other|Premenstrual Dysphoric Disorder|Depressive Disorder, Major|Pain Unspecified

Phase 2: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT02617537

P3

Withdrawn

Other

2017-09-01

JapicCTI-121984

P3

Completed

Endometriosis

2015-02-01

JapicCTI-132193

P3

Completed

Unknown

2015-02-01

NCT01892904

P3

Completed

Pain Unspecified

2015-01-01

Recent News Events

Date

Type

Title